| The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series H Ragan, E Autry, T Bomersback, J Hewlett, L Kormelink, J Safirstein, ... Pediatric Pulmonology 57 (2), 411-417, 2022 | 19 | 2022 |
| Patients and families experience with pharmacist care at cystic fibrosis foundation accredited clinics DC Young, E Autry, JT Zobell, L Kormelink, K Homa, KA Sabadosa, ... Pediatric pulmonology 54 (8), 1216-1224, 2019 | 18 | 2019 |
| Retrospective review of vancomycin monitoring via trough only versus two‐point estimated area under the curve in pediatric and adult patients with cystic fibrosis B Mitchell, L Kormelink, R Kuhn, A Schadler, E Autry Pediatric Pulmonology 58 (1), 239-245, 2023 | 4 | 2023 |
| Geriatric and student perceptions following student-led educational sessions K Janzen, LN Kormelink, L Saum, SA Nisly INNOVATIONS in pharmacy 9 (1), 1-1, 2018 | 2 | 2018 |
| Evaluation of a pharmacist‐led smoking cessation service in a pulmonary clinic S Andras, E Sherwin, C Bodreau, A Schadler, L Kormelink Journal of the American College of Clinical Pharmacy 6 (10), 1084-1090, 2023 | 1 | 2023 |
| The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis post-liver transplantation HH Ragan, E Autry, T Bomersback, J Hewlett, L Kormelink, J Safirstein, ... PEDIATRIC PULMONOLOGY 55, S349-S350, 2020 | 1 | 2020 |
| A decade of change: The evolution of pharmacy services at US cystic fibrosis centers PM Grube, EB Autry, LN Kormelink, DC Young, JT Zobell, ZN Bhakta, ... Pediatric Pulmonology 59 (3), 652-661, 2024 | | 2024 |
| Assessment of long‐term medication adherence with cystic fibrosis: An integrated approach T Platt, LN Kormelink, EB Autry, SJ Rossoll, RJ Kuhn Pediatric Pulmonology 59 (2), 458-464, 2024 | | 2024 |
| Efficacy of elexacaftor/tezacaftor/ivacaftor in decreasing severe cystic fibrosis-related exacerbations: a retrospective, within-group study C Rhudy, L Kormelink, B Taylor, S Hegnauer, E Autry, M Zeltner, T Platt | | 2024 |
| 376 Impact of total care pharmacy services provided by a health system specialty pharmacy on long-term medication adherence in peoplewith cystic fibrosis L Kormelink, T Platt, E Autry, S Rossoll, R Kuhn Journal of Cystic Fibrosis 22, S190, 2023 | | 2023 |
| 431 Evolution of pharmacy services at US CFF-accredited centers: 10 years later P Grube, E Autry, L Kormelink, D Young, J Zobell, Z Bhakta, R Kuhn Journal of Cystic Fibrosis 22, S226, 2023 | | 2023 |
| 436 Documentation practices of cystic fibrosis pharmacists: an opportunity for discipline-wide quality improvement H Phan, J Rosano, J Huntman, J Safirstein, L Kormelink, E Seamans, ... Journal of Cystic Fibrosis 22, S229, 2023 | | 2023 |
| Retrospective review of vancomycin monitoring via trough only versus two-point estimated area under the curve in pediatric and adult patients with cystic fibrosis (vol 58, pg … B Mitchell, L Kormelink, R Kuhn, A Schadler, E Autry PEDIATRIC PULMONOLOGY 58 (6), 1838-1838, 2023 | | 2023 |
| 502 Retrospective reviewof vancomycin trough versus area under the curve monitoring in pediatric and adult patients with cystic fibrosis B Mitchell, L Kormelink, R Kuhn, E Autry Journal of Cystic Fibrosis 21, S284, 2022 | | 2022 |
| 252 Real-world efficacy of elexacaftor/tezacaftor/ivacaftor in decreasing cystic fibrosis pulmonary exacerbations in health-system based specialty pharmacy patients C Rhudy, L Kormelink, B Taylor, S Hegnauer, E Autry, M Zeltner Journal of Cystic Fibrosis 21, S150, 2022 | | 2022 |
| A PROACTIVE, PHARMACY-DRIVEN APPROACH TO RAPID INITIATION OF CFTR MODULATORS: MEETING THE NEEDS OF OUR PATIENTS L Kormelink, E Autry, RJ Kuhn, C Duncan, B Taylor, S Hegnauer, A Cox PEDIATRIC PULMONOLOGY 55, S253-S254, 2020 | | 2020 |
| Student-led educational sessions: participant perceptions KM Janzen, L Kormelink, L Saum, SA Nisly PHARMACOTHERAPY 36 (12), E223-E224, 2016 | | 2016 |
| Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Decreasing Severe Cystic Fibrosis-Related Exacerbations in Specialty Pharmacy Patients and Vulnerable Subgroups: A Retrospective … C Rhudy, L Kormelink, B Taylor, S Hegnauer, E Autry, M Zeltner, T Platt Tezacaftor/Ivacaftor in Decreasing Severe Cystic Fibrosis-Related …, 0 | | |
